Connect with us
[ad_1] Newswise — Boston – A drug that simultaneously strikes cancer cells’ growth circuits and pipeline to the bloodstream produced encouraging results in a clinical trial...
[ad_1] Newswise — Boston – Belzutifan significantly reduced the risk of progression of clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer,...
[ad_1] Newswise — Boston – The Pancreatic Cancer Action Network (PanCAN), a leading non-profit in the fight against pancreatic cancer, has awarded Dana-Farber Cancer Institute researchers...
[ad_1] RESEARCH SUMMARY Study Title: Early Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer Publication: Journal of Clinical Oncology Dana-Farber Cancer Institute authors: Jeremiah Wala; MD, PhD,...
[ad_1] RESEARCH SUMMARY Publication: Nature Genetics https://www.nature.com/articles/s41588-023-01307-z Dana-Farber Cancer Institute author: Cigall Kadoch, PhD, Summary: A new class of oral drugs can inhibit a wide...
[ad_1] RESEARCH SUMMARY Study Title: An atlas of substrate specificities for the human serine/threonine kinome Publication: Nature (Online) January 11, 2023 https://www.nature.com/articles/s41586-022-05575-3 Dana-Farber Cancer Institute author:...
[ad_1] Newswise — BOSTON –A combination of two next-generation immunotherapy drugs has shown promising clinical activity in treating patients with refractory metastatic colorectal cancer, a disease...
[ad_1] Newswise — Every year, up to 1% of patients with chronic lymphocytic leukemia (CLL), a slow-growing blood cancer, have their disease transform into a far...